Allosteric effects of R- and S-citalopram on the human 5-HT transporter: Evidence for distinct high- and low-affinity binding sites

European Journal of Pharmacology

Volumn 567, Issue 1-2, 2007, Pages 1-9

  Plenge, Per ^a,b   Gether, Ulrik ^b   Rasmussen, Søren G ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 HT; 3H imipramine; 3H paroxetine; 3H S citalopram; Allosteric binding site; Dissociation; Human SERT; R citalopram; S citalopram

Indexed keywords

CITALOPRAM; FLUOXETINE; IMIPRAMINE; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SERTRALINE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN COS1; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG UPTAKE; ENANTIOSELECTIVITY; FIBROBLAST; GENE MUTATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; WILD TYPE;

ALLOSTERIC REGULATION; ANIMALS; ANTIDEPRESSIVE AGENTS; BINDING SITES; CERCOPITHECUS AETHIOPS; CITALOPRAM; COS CELLS; HUMANS; MUTAGENESIS, SITE-DIRECTED; PAROXETINE; RADIOLIGAND ASSAY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM;

EID: 34249031195     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.03.055     Document Type: Article

References (30)

1. Barker E.L., Perlman M.A., Adkins E.M., Houlihan W.J., Pristupa Z.B., Niznik H.B., and Blakely R.D. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis - an aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J. Biol. Chem. 273 (1998) 19459-19468
2. Chen N.H., Reith M.E., and Quick M.W. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. 447 (2004) 519-531
3. Chen F.H., Larsen M.B., Sánchez C., and Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol. 15 (2005) 193-198
4. Chen F.H., Larsen M.B., Neubauer H.A., Sánchez C., Plenge P., and Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J. Neurochem. 92 (2005) 21-28
5. EL Mansari M., Sánchez C., Chouvet G., Renaud B., and Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30 (2005) 1269-1277
6. Erreboe I., Plenge P., and Mellerup E.T. Differences in brain 5-HT transporter dissociation rates among animal species. Pharmacol. Toxicol. 76 (1995) 376-379
7. Fabre V., and Hamon M. Mechanisms of action of antidepressants: new data from escitalopram. Encep. Rev. Psychiat. Clin. Biol. Ther 29 (2003) 259-265
8. Fillion G., Rousselle J.C., Massot O., Zifa E., Fillion M.P., and Prudhomme N. A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT1B/1D receptors. Behav. Brain Res. 73 (1995) 313-317
9. Fish E.W., Faccidomo S., Gupta S., and Miczek K.A. Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. J. Pharmacol. Exp. Ther. 308 (2004) 474-480
10. Gether U., Marray T., Schwartz T.W., and Johansen T.E. Stable expression of high-affinity NK1 (substance-P) and NK2 (neurokinin-A) receptors but low affinity NK3 (neurokinin-B) receptors in transfected CHO cells. FEBS Lett. 296 (1992) 241-244
11. Gether U., Andersen P.H., Larsson O.M., and Schousboe A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol. Sci. 27 (2006) 375-383
12. Henry L.K., Field J.R., Adkins E.M., Parnas M.L., Vaughan R.A., Zou M.F., Newman A.H., and Blakely R.D. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 281 (2006) 2012-2023
13. Johansen T.E., Scholler M.S., Tolstoy S., and Schwartz T.W. Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors. FEBS Lett. 267 (1990) 289-294
14. Larsen M.B., Elfving B., and Wiborg O. The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors - a species-scanning mutagenesis study. J. Biol. Chem. 279 (2004) 42147-42156
15. Moore N., Verdoux H., and Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. 20 (2005) 131-137
16. Mork A., Kreilgaard M., and Sánchez C. The R-enantiomer of citalopram increase in extracellular 5-HT counteracts escitalopram-induced in the frontal cortex of freely moving rats. Neuropharmacology 45 (2003) 167-173
17. Mortensen O.V., Kristensen A.S., and Wiborg O. Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants. J. Neurochem. 79 (2001) 237-247
18. Neubauer H.A., Hansen C.G., and Wiborg O. Dissection of an allosteric mechanism on the serotonin transporter, a cross-species study. Mol. Pharmacol. 69 (2006) 1242-1250
19. Plenge P., and Mellerup E.T. Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes. Eur. J. Pharmacol. 119 (1985) 1-8
20. Plenge P., Mellerup E.T., Honore T., and Honore P.L. The activity of 25 paroxetine/femoxetine structure variants in various reactions, assumed to be important for the effect of antidepressants. J. Pharm. Pharmacol. 39 (1987) 877-882
21. Plenge P., Mellerup E.T., and Nielsen M. Inhibitory and regulatory binding-sites on the rat-brain serotonin transporter - molecular-weight of the [3H]paroxetine and [3H]citalopram binding-proteins. Eur. J. Pharmacol., Mol. Pharmacol. Sect. 189 (1990) 129-134
22. Plenge P., Mellerup E.T., and Laursen H. Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur. J. Pharmacol., Mol. Pharmacol. Sect. 206 (1991) 243-250
23. Plenge P., and Mellerup E.T. An affinity-modulating site on neuronal monoamine transport proteins. Pharmacol. Toxicol. 80 (1997) 197-201
24. Plenge P., and Wiborg O. High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci. Lett. 383 (2005) 203-208
25. Rasmussen S.G.F., and Gether U. Purification and fluorescent labelling of the human serotonin transporter. Biochemistry 44 (2005) 3494-3505
26. Sánchez C. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur. J. Pharmacol. 464 (2003) 155-158
27. Storustovu S.I., Sánchez C., Porzgen P., Brennum L.T., Larsen A.K., Pulis M., and Ebert B. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br. J. Pharmacol. 142 (2004) 172-180
28. Torres G.E., Gainetdinov R.R., and Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci 4 (2003) 13-25
29. Wennogle L.P., and Meyerson L.R. Serotonin modulates the dissociation of [3H]imipramine from human-platelet recognition sites. Eur. J. Pharmacol. 86 (1982) 303-307
30. Yamashit A.A., Singh S.K., Kawate T., Jin Y., and Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 437 (2005) 215-223